Jose Lopez, MD
Psychiatry · Homestead, FLNPI 1669515730
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Chiesi USA, Inc. at 44.4% of the total. Reporting peaked in 2023 at $4,176 and has fallen 93.3% since, to $282 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $34.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$4K
- Supernus Pharmaceuticals, Inc.$824
- Sunovion Pharmaceuticals Inc.$525
- Teva Pharmaceuticals USA, Inc.$508
- AbbVie$492
- Takeda Pharmaceuticals U.S.A., Inc.$343
- plus $2K from 18 others
Across 617 payments — averaging $2373.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$538K
- Exeltis, USA Inc.$314K
- Novo Nordisk AS$215K
- GSK$202K
- E.r. Squibb & Sons, L.L.C.$104K
- Chiesi USA, Inc.$89K
- plus $3K from 1 others
What the payments were for
- Travel & lodging$3,35340%
- Food & beverage$4,93858%
- Education$1892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 4 | $3,763 |
| Supernus Pharmaceuticals, Inc. | 30 | $824 |
| Sunovion Pharmaceuticals Inc. | 24 | $525 |
| Teva Pharmaceuticals USA, Inc. | 28 | $508 |
| AbbVie(2 entities) | 46 | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $343 |
| Neurocrine Biosciences, Inc. | 17 | $298 |
| Otsuka America Pharmaceutical, Inc. | 15 | $297 |
| Alkermes, Inc. | 10 | $198 |
| Johnson & Johnson | 4 | $169 |
| Axsome Therapeutics, Inc. | 9 | $158 |
| Almatica Pharma LLC | 7 | $134 |
| Vanda Pharmaceuticals Inc. | 7 | $129 |
| E.r. Squibb & Sons, L.L.C. | 5 | $124 |
| AstraZeneca | 1 | $115 |
| Abbott | 2 | $96 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $89 |
| Eisai Inc. | 3 | $55 |
| Lundbeck LLC | 2 | $42 |
| Indivior Inc. | 2 | $35 |
| Adlon Therapeutics L.p. | 2 | $31 |
| Tempus AI, Inc | 1 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,481 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 37 | $52,187 |
| Mirtazapine | 5,649 | $48,666 |
| Aripiprazole | 229 | $40,634 |
| Chlordiazepoxide Hcl | 3,619 | $38,556 |
| Olanzapine | 353 | $35,917 |
| RexultiBrexpiprazole | 16 | $22,991 |
| Quetiapine Fumarate | 1,956 | $22,106 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 150 | $20,045 |
| Clonazepam | 2,363 | $19,802 |
| TrintellixVortioxetine Hydrobromide | 42 | $19,495 |
| Temazepam | 3,015 | $16,526 |
| Escitalopram Oxalate | 3,863 | $14,280 |
| Lurasidone Hcl | 57 | $11,136 |
| Trifluoperazine Hcl | 312 | $9,538 |
| Trazodone Hcl | 2,164 | $9,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $492 | $59,00851 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $297 | $22,99116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $343 | $19,49542 claims |
| Almatica Pharma LLCSertraline Hcl | $134 | $9,1652,688 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Homestead
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.